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Despite the successful development, licensing and distribu-
tion methods of vaccines against COVID-19 (1, 2), the num-
ber of newly reported cases and deaths continued to rise 
globally into the northern hemisphere summer of 2021 (3). 
Prior trends of decreasing prevalence were being reversed in 
some populations where the Delta variant had become dom-
inant, leading to estimates of a substantially higher trans-
missibility for Delta compared to Alpha (4). In addition, 
globally, as of July 2021, only 13% of the population were 
fully vaccinated while only 1% of people in low income 
countries had received even one dose (5). Despite the poten-
tial for reduced growth during the northern hemisphere 
summer, many countries are evaluating the possibility of a 
further large wave of infections in the autumn, driven by 
the Delta variant. 
The vaccine roll-out in England started with the oldest 
and most vulnerable groups, beginning in December 2020. 
Since then, there has been a strong correlation between age, 
vaccine type and date of vaccination, with individuals re-
ceiving the same vaccine for first and second dose. Initially, 
healthcare workers and older adults received BNT162b2 be-
fore doses were switched to ChAdOx1 for many people be-
tween the ages of 40 and 80 and some younger people. The 
program then switched back to BNT162b2 for those below 
the age of 40 (also using small numbers of mRNA-1273 vac-
cine). Subsequently, from September 2021, the vaccination 
program was expanded to include children from the age of 
12 years. 
The incidence of reverse transcription-polymerase chain 
reaction (RT-PCR) confirmed cases of COVID-19 increased 
substantially in England after the Delta variant became es-
tablished during April to May 2021 (6). Over the same peri-
od, the UK government proceeded with its gradual 
relaxation of social distancing (roadmap) (7) with the end-
ing of almost all legal restrictions in England on 19 July 
2021 (8). While a much lower proportion of COVID-19 cases 
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SARS-CoV-2 infections were rising during early summer 2021 in many countries associated with the Delta 
variant. We assessed RT-PCR swab-positivity in the REal-time Assessment of Community Transmission-1 
(REACT-1) study in England. We observed sustained exponential growth with average doubling time (June-
July 2021) of 25 days driven by complete replacement of Alpha variant by Delta, and by high prevalence at 
younger less-vaccinated ages. Unvaccinated people were three times more likely than double-vaccinated 
people to test positive. However, after adjusting for age and other variables, vaccine effectiveness for 
double-vaccinated people was estimated at between ~50% and ~60% during this period in England. 
Increased social mixing in the presence of Delta had the potential to generate sustained growth in 
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resulted in hospitalisations in England versus a comparable 
period of growth during autumn 2020, exponential growth 
in hospitalisations was still observed from mid-June 2021 
(6). 
With first data collection starting in May 2020, we es-
tablished the REal-time Assessment of Community Trans-
mission-1 (REACT-1) study to track the spread of the 
COVID-19 pandemic in England and improve situational 
awareness (9, 10). The study involves obtaining a self-
administered throat and nose swab for reverse transcriptase 
polymerase chain reaction (RT-PCR) from ~100,000 or more 
people during two to three weeks each month, based on 
non-overlapping random samples of the population in Eng-
land at ages 5 years and above (see materials and methods). 
As well as information on swab-positivity, we collect demo-
graphic and contextual data including (since January 2021) 
on vaccination history. By July 2021, ~1.8 million people had 
taken part (table S1). Here, we describe the key patterns of 
SARS-CoV-2 infections for round 12 (20 May to 7 June 2021) 
and round 13 (24 June to 12 July 2021) during the third 
wave of the epidemic in England. (9, 10). 
Valid RT-PCR results were obtained from 108,911 partic-
ipants in round 12 and 98,233 participants in round 13 (ta-
ble S1). 
 
Prevalence and growth 
Prevalence of infection with SARS-CoV-2 increased substan-
tially in England between rounds 12 and 13 (Fig. 1) as the 
third wave took hold, linked to the rapid replacement of 
Alpha by Delta variant. In round 13, between 24 June and 12 
July 2021, we found 527 positives from 98,233 swabs giving 
a weighted prevalence of 0.63% (0.57%, 0.69%, 95% credible 
interval [CrI]), and, on average, a greater than four-fold rise 
compared with the weighted prevalence in round 12 of 
0.15% (0.12%, 0.18%, CrI) (table S1). The prevalence in round 
13 was similar to that observed in early October 2020 and 
late January 2021 during, respectively, the rise and fall of 
the second wave (Fig. 1). 
The Delta variant completely replaced Alpha during the 
period of our study, consistent with genomic data from out-
break investigation and routine surveillance (11). Of the 254 
lineages determined for round 13, 100% were the Delta vari-
ant, compared with round 12 during which 36 of 46 (78.3%) 
were Delta and the remaining 10 were Alpha variant. 
Growth of Delta against Alpha for round 10 (11 to 30 March 
2021) to round 13 corresponded to a daily growth rate ad-
vantage of 0.14 (0.10, 0.20) for Delta, which, in turn, implied 
an additive R advantage of 0.86 (0.63, 1.23) (Fig. 1). This is 
consistent with estimates based on trends in the proportion 
of positive PCR assays where S gene was not detected (pre-
sumed to be Delta, (12)) and on differences in household 
attack rate for households where Delta was identified rather 
than Alpha (13). Within the Delta variant, we did not detect 
the K417N mutation associated with the AY.1 and AY.2 line-
ages. Under the assumption that REACT-1 participants pro-
vide an unbiased sample of infections, we can exclude, with 
95% confidence, a population prevalence of non-Delta line-
ages greater than 0.004%, corresponding to 2,350 infections 
in England on average during round 13. 
Nationally, we observed an exponential trend in preva-
lence with sustained growth for rounds 12 to 13 (between 20 
May and 12 July 2021) (Fig. 1 and table S2) despite England 
having one of the highest adult vaccination rates interna-
tionally (5). Averaging over the period of each of rounds 12 
and 13 separately, we estimated the reproduction number R 
at 1.44 (1.20, 1.73, CrI) (round 12) and 1.19 (1.06, 1.32, CrI) 
(round 13), corresponding to doubling times of 11 (7, 23, CrI) 
days and 25 days (with a lower CrI of 15 days) respectively. 
Across rounds 12 to 13, R was 1.28 (1.24, 1.31, CrI) with a 
doubling time of 17 (15, 19, CrI) days. Patterns of growth for 
the period of the study were robust when considering alter-
native definitions of positivity, such as only non-
symptomatic individuals or positive samples with lower cy-




Alongside the rapid rise of the Delta variant, recent growth 
in England appears to have been driven by younger age 
groups (table S3 and fig. S1). For example, weighted preva-
lence in round 13 was nine-fold higher in 13-17 year olds at 
1.56% (1.25%, 1.95%, CrI) compared with 0.16% (0.08%, 
0.31%, CrI) in round 12. Similar patterns were observed in 
England for the same period in a longitudinal household 
study (14). In contrast, at ages 65-74 years, the increase in 
weighted prevalence from round 12 to round 13 was three- 
to four-fold from 0.07% (0.04%, 0.12%, CrI) to 0.25% (0.19%, 
0.34%, CrI) respectively. More generally, participants aged 
between 5 and 24 years were over-represented among in-
fected people in our study, contributing 50% of infections 
(weighted age-standardised) while only representing 25% of 
the population of England aged 5 years or above (15). There-
fore, whether because of mixing patterns, infectiousness or 
susceptibility, this group was driving transmission and, dur-
ing a period of exponential growth, any vaccination targeted 
at the younger ages would have a disproportionate impact 
in slowing the epidemic (16). 
 
Prevalence among vaccinated and unvaccinated 
Participants who reported having received two doses of vac-
cine were at substantially reduced risk of testing positive 
compared with those who reported not being vaccinated. 
For round 13, prevalence of swab positivity among those 
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(1.03%, 1.41%, CrI) compared with 0.40% (0.34%, 0.48%, CrI) 
among those who had received two doses of vaccine (table 
S3). The ratio of prevalence for unvaccinated to double-
vaccinated individuals for round 12 was similar with a prev-
alence of 0.24% (0.18%, 0.33%, CrI) in those unvaccinated 
compared with 0.07% (0.05%, 0.10%, CrI) in those reporting 
two doses (table S3). 
However, these estimates conflate the effect of vaccina-
tion with other correlated variables such as age, which is 
strongly associated with likelihood of having been vaccinat-
ed and also acts as a proxy for differences in behavior across 
the age groups. Specifically, in England, few children and 
young people under the age of 18 years have been vaccinat-
ed twice, while few over the age of 65 years remain unvac-
cinated (Table 1 and Fig. 1). We therefore restricted the 
analyses to those aged 18 to 64 years (n = 64,415 in round 
12, n = 57,457 in round 13), which permitted direct contrast 
of infection rates between double-vaccinated and unvac-
cinated groups (Table 1). 
At these ages, we compared swab-negatives with i) all 
swab-positives and ii) the subset of swab-positives who were 
symptomatic, that is reporting one or more common 
COVID-19 symptoms in the month prior to testing (fever, 
loss or change of sense of smell or taste, new persistent 
cough). After adjusting for age, sex, region, ethnicity and 
index of multiple deprivation (IMD) (17), for all swab-
positives, we estimated vaccine effectiveness (VE) in round 
12 of 64% (11%, 85%, 95% confidence interval [CI]) and 49% 
(22%, 67%, CI) in round 13 among people who had received 
two doses of vaccine of any type. For those with symptoms 
we estimated VE of 83% (19%, 97%, CI) in round 12 and 59% 
(23%, 78%, CI) in round 13 (Table 2). 
Independent data on vaccination status was provided 
for 57,338 (89%) participants aged 18 to 64 in round 12 con-
senting to data linkage, and 49,923 (87%) in round 13 (ma-
terials and methods). Using these linked data, we estimated 
adjusted VE at 75% (35%, 90%, CI) in round 12 and 62% 
(38%, 77%, CI) in round 13. The apparently higher VE for the 
linked participants reflected differences in odds of infection 
among the linked and unlinked groups (table S4), suggest-
ing possible bias introduced by consent to linkage, but also 
some misclassification of vaccine status in the self-reported 
data (table S5). Since reported dates of vaccination were 
more reliable in the linked data, we used those data to ex-
amine the effect of including a lag period of 14 days after 
the second vaccination and observed similar odds ratios for 
zero lag and 14 days lag following the second dose (Table 1). 
In addition, we observed a similar unweighted prevalence of 
swab-positivity among double-vaccinated individuals who 
did and did not report prior infection more than 28 days 
before their swab (table S5), suggesting in our study that 
prior infection did not materially affect the estimate of VE. 
Moreover, the strong correlation between age, vaccine type 
and time-since-vaccination in England, together with lim-
ited numbers, prevented us from being able to reliably as-
sess the impact of vaccine type or time-since-infection 
independently of age. 
While vaccination was associated with lower prevalence 
of swab-positivity, there remained potential for large num-
bers of people who had received two doses of vaccine to be-
come infected. During the period of round 12, we 
extrapolated from our data that 29% of infections in Eng-
land occurred in double-vaccinated people, rising to 44% 
during the period of round 13. These increases in prevalence 
in vaccinated individuals in round 13 could be driven by 
increased social mixing, a higher proportion of infections 
being Delta variant or by waning of protection from infec-
tion. Also, although lower than for unvaccinated individuals, 
nearly one in 25 double-vaccinated individuals (3.84% 
[2.81%, 5.21%, CrI]) tested swab-positive if they reported 
contact with a known COVID-19 case (table S6). 
 
Cycle threshold values 
We analyzed Ct values associated with positive results 
among vaccinated and unvaccinated individuals as a meas-
ure of viral load. For all positives in round 13, at ages 18 to 
64 years, median Ct value was higher for vaccinated partici-
pants at 27.6 (25.5, 29.7, CI for median) compared with un-
vaccinated at 23.1 (20.3, 25.8, CI) (positive defined as N gene 
Ct <37 or both N gene and E gene positive; see materials 
and methods) (Fig. 2 and table S7). The higher Ct values 
among vaccinated people may suggest lower infectiousness 
(18), consistent with transmission studies conducted when 
the Alpha variant was dominant, in which vaccinated indi-
viduals were at substantially lower risk of passing on infec-
tion (19). As a secondary analysis, we reduced the Ct 
threshold for positivity to capture strong positives, which 
resulted in a smaller difference in median Ct values between 
vaccinated and unvaccinated individuals (Fig. 2, C and D). 
At the same time, our estimate of VE for those who reported 
having received two doses of vaccine increased to 54% (29%, 
71%, CI) for a Ct threshold of 35, plateauing between 57% 
(32%, 72%, CI) and 58% (33%, 73%, CI) for a Ct threshold of 
33 and 27 respectively (table S7). 
 
Time-series of infections, hospital admissions and 
deaths 
We next investigated how swab-positivity measured in 
REACT-1 related to daily hospital admissions and deaths in 
publicly available data (6), finding a best fitting lag between 
swab-positivity and hospitalisations of 20 days and between 
swab-positivity and deaths of 26 days (Fig. 3). At these lags, 
from early February 2021, there was a clear divergence be-
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out of England’s mass vaccination campaign, with a smaller 
divergence between swab-positivity and hospitalisations. 
However, as the Delta variant became dominant in mid-
April 2021, the associations between infections and hospital-
isations and deaths began to re-converge, both for people 
below and above 65 years (fig. S2). 
 
Geographical variation 
At the regional level, estimates of R were consistent with the 
overall trend within round 13. Prevalence in round 13 was 
highest in London at 0.94% (0.76%, 1.16%, CrI) up from 
0.13% (0.08%, 0.20%, CrI) in round 12 (table S3). There was 
a suggestion of a possible slowing of the rise in London in 
the most recent data, although with wide confidence inter-
vals (table S8). 
At the sub-regional level, there was a suggestion of 
prevalence of infection decreasing in some areas and in-
creasing in others (fig. S3). For example, in the North West 
of England, high prevalence in a large urban area covering 
Greater Manchester and Lancashire during the first half of 
round 13 was less evident in the second half, whereas preva-
lence increased between the first and second halves in near-
by south Yorkshire, part of the Yorkshire and The Humber 
region. These data are indicative of rapidly changing local 
spread of the virus within the context of the national expo-
nential rise in infections. 
 
Ethnicity, household size and neighborhood  
deprivation 
Ethnicity, household size and area levels of deprivation 
jointly contributed to the risk of higher prevalence of swab-
positivity, in addition to age. Unadjusted prevalence (table 
S3) showed: highest prevalence in people of Black ethnicity 
at 1.21% (0.75%, 1.93%, CrI) compared with 0.59% (0.53%, 
0,65%, CrI) in people of white ethnicity; highest prevalence 
in those in the largest households of 6 or more people at 
1.35% (0.90%, 2.01%, CrI) compared with 0.44% (0.32%, 
0.61%, CrI) and 0.44% (0.36%, 0.53%, CrI) in single and two 
person households respectively; and highest prevalence in 
participants living in the most deprived neighborhoods at 
0.82% (0.65%, 1.04%, CrI) compared with the least deprived 
at 0.48% (0.39%, 0.59%, CrI). Prior rounds of REACT-1 have 
shown different ethnicities at increased prevalence at differ-
ent times, consistently higher prevalence of infection in 
larger households and usually increased prevalence in more 
deprived neighborhoods (20–25). In models including each 
of the above variables, similar patterns were observed in the 
odds of testing positive, although odds were reduced when 
all three of the above variables were considered jointly, to-
gether with age, sex, region and keyworker status (table S9). 
Age remained an important predictor of swab-positivity in 
these mutually adjusted models. Also, in these analyses, 
women had lower odds of infection than men at 0.80 (0.67, 
0.96, CrI) in round 13, although not in round 12 at 1.34 
(0.93, 1.92, CrI) (tables S3 and S9); this difference may be 
related to increased social mixing associated with England’s 
progression in the Euro 2020 football competition during 
June and July 2021, as was seen previously in Scottish data, 
reflecting their earlier exit from the competition (26). 
 
Discussion 
We report a rapidly rising prevalence of infection in Eng-
land during 20 May to 12 July 2021 associated with the re-
placement of Alpha by Delta variant, in a highly vaccinated 
population. Our central estimate of VE against all SARS-
CoV-2 infections for two doses of vaccine (self-report) was 
49% in the most recent data, increasing to 58% when we 
defined effectiveness only for strong positives, and 62% in 
the linked data. These estimates are lower than some others 
(19, 27, 28), but consistent with more recent data from Israel 
(29). 
Estimates of VE are not absolute but will vary depend-
ing on a variety of factors. Our estimates were higher when 
we restricted our analyses to people reporting symptoms of 
COVID-19 in the previous month and to those who consent-
ed to linkage of health records, although still lower than 
those from routine testing of symptomatic people present-
ing for RT-PCR in England (27). Unlike routine testing, our 
data are based on a random sample of the population and 
include asymptomatic people, as well as symptomatic indi-
viduals who may not present for testing; our results may 
therefore give a less biased representation of infection risk. 
Also, our estimated effectiveness was lower than that from a 
longitudinal household survey which included asymptomat-
ic individuals but which was conducted prior to the emer-
gence of Delta, where vaccine status was based on a mix of 
self-reported and linked data (19). 
More generally, estimates of VE may depend on vaccine 
type, interval between doses, possible waning over time and 
the extent of past natural infection among the comparator 
(unvaccinated) group. 
We show that the third wave of infections in England 
was being driven primarily by the Delta variant in younger, 
unvaccinated people. This focus of infection offers consider-
able scope for interventions to reduce transmission among 
younger people, with knock-on benefits across the entire 
population. Also, given the rapid rise of the Delta variant 
that occurred in Europe, the USA, South Asia and elsewhere, 
and its estimated increased transmissibility, patterns in 
England were informative of what was subsequently ob-
served elsewhere. In our data, the highest prevalence of in-
fection during June to July 2021 was among 13 to 24 year 
olds. In the UK, the Joint Committee on Vaccinations and 
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tion should be offered to all 16 and 17 year olds and then in 
September 2021 further extended the UK program to in-
clude children aged 12 to 15 years as has been done in the 
USA and some other countries. This expansion of the vac-
cination program to those at highest risk of infection has 
the potential to reduce transmission in the autumn and 
winter 2021 as levels of social mixing, including indoors, 
increase (30). Also, development of vaccines against Delta 
may be warranted in the light of evidence of antigenic 
change measured by neutralization (31) and the relationship 
between neutralization titer and protection from mild dis-
ease (32). 
Estimates of VE against serious outcomes of greater 
than 90% have been reported for those who have received 
two doses of either BNT162b2 (33) or ChAdOx1-S (34) vac-
cines. This is in keeping with our observation of a weaken-
ing of the association between infections and 
hospitalisations and deaths from mid-February to early 
April 2021 when Alpha variant was dominant. However, in 
our more recent data (since mid-April 2021), infections and 
hospitalisations began to re-converge, potentially reflecting 
the increased prevalence and severity of Delta compared 
with Alpha (35), a changing age mix of hospitalised cases to 
younger ages, and possible waning of protection (29, 36). 
Our study has limitations. One estimate of effectiveness 
was based on self-reported vaccine status, because we could 
only obtain linked vaccination data for the subset of partici-
pants who gave consent, with individuals who did and did 
not consent to linkage appearing to have different patterns 
of swab-positivity across the vaccinated and unvaccinated 
groups. Since age, date of vaccination and vaccine type are 
so strongly correlated in England, and with limitations in 
numbers, we were wary of introducing a time variable into 
the analyses to investigate the waning of VE explicitly. 
However, it should be noted that the design of the study, 
based on estimation of infection prevalence from independ-
ent samples within (as well as across) separate rounds, con-
ducted monthly, itself provides strong control for any time 
effects. 
Over the course of the study since round 1 in May 2020, 
toward the end of the first lockdown in England, we ob-
served a gradual reduction in response rates, from 30.5% in 
round 1 to 11.7% in round 13. These rates are conservative 
estimates since they are based on numbers of swabs with a 
valid RT-PCR result compared to the total number of letters 
of invitation sent out, some of which may have been re-
turned, sent to the wrong address or left unopened by the 
recipient. Nonetheless, the drop in response rates means 
that our sample may be becoming less representative, par-
ticularly in some groups such as young people (18 to 24 
years) and those living in the most deprived areas where 
response rates by round 13 had fallen to 4.2% and 5.1% re-
spectively. It should be noted, however, that these response 
rates have been achieved without use of financial or other 
incentives. 
Our method of sampling was designed initially to 
achieve sufficient numbers in each lower-tier local authority 
(LTLA) in England so that we could analyze sub-regional 
trends and also, by weighting the sample, provide estimates 
of prevalence that were representative of the population of 
England. While previously we had aimed to achieve approx-
imately equal numbers of people in our sample by LTLA, in 
rounds 12 and 13 we switched to sampling in proportion to 
population in order to capture greater resolution in inner 
city areas, which were relatively under-represented in our 
previous sampling regimen. In either case, as we re-weight 
the sample according to the national population profile, 
weighted prevalence should be comparable across rounds, 
albeit with lower precision in later rounds because of the 
lower response rates. 
In conclusion, we have shown rapid exponential growth 
of SARS-CoV2 prevalence during the third wave in England 
at a time when Delta variant became dominant. The rapid 
roll-out of the vaccination program in England has so far 
limited the number of infections and serious cases relative 
to the unvaccinated population. Level or declining preva-
lence were observed during summer 2021 in the northern 
hemisphere, reflecting school vacations, greater time spent 
outdoors and reduced social interactions. But without addi-
tional interventions, increased mixing, including indoors, 
during the autumn and winter in the presence of the Delta 
variant may lead to renewed growth, even at high levels of 
vaccination. Continued surveillance to monitor the spread 
of the epidemic is therefore required. 
 
Materials and methods 
The REACT-1 study methods have been described elsewhere 
(9). Briefly, at each round, we sent an invitation by post to 
named individuals from the list of patients registered with a 
National Health Service (NHS) general practitioner in Eng-
land, obtained from NHS Digital, covering almost the entire 
population. We included all 317 lower-tier local authorities 
(LTLAs) in England, and by combining the Isles of Scilly 
with Cornwall and the City of London with Westminster, we 
report results across 315 LTLAs overall. 
For round 1 to round 11 we aimed to obtain approxi-
mately equal numbers of participants in each LTLA to be 
powered to provide local estimates of prevalence. From 
round 12 onwards, we adjusted the sampling procedure to 
select the sample randomly in proportion to population at 
LTLA level thus obtaining more samples in higher popula-
tion density LTLAs in inner urban areas. However, we en-
sured that data were comparable across rounds as we re-
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England as a whole (see below). 
For those registering to participate, we obtained age, 
sex, address and residential postcode from the NHS register 
and collected additional information on demographics, 
health and lifestyle via online or telephone questionnaire. 
This included information on ethnicity, smoking, household 
size, key worker status, contact with a known or suspected 
COVID-19 case, and whether, at time of survey, participants 
had experienced one or more of 29 symptoms in the past 
week or past month (participants not reporting symptoms 
may have developed symptoms later but these were not cap-
tured). Participants were also asked for consent to longer-
term follow-up through linkage to their NHS records includ-
ing data from the national immunization program. The 
questionnaires are available on the study website (37). 
Response rates have varied by age and over time and 
place, and are available for each round (“For Researchers: 
REACT-1 Study Materials” (37)). Overall response rate was 
defined as the percentage of invitees from whom we re-
ceived a valid swab result; this was 20.4% across all rounds, 
and 13.4% and 11.7% for rounds 12 and 13 respectively. In 
round 13, response rate varied by age from 4.2% at ages 18 
to 24 years to 24% at ages 65 to 74 years and by IMD decile 
from 5.1% in the most deprived areas to 20.8% in the least 
deprived. 
Participants were requested to provide a self-
administered throat and nose swab (obtained by parent or 
guardian for children aged 5 to 12 years) following written 
and video instructions. Swabs were placed into a dry tube 
(no solution or preservative), refrigerated at home, picked 
up by courier and then sent chilled to a single commercial 
laboratory for testing for SARS-CoV-2 by RT-PCR. 
 
Ct threshold and laboratory calibration experiments 
We tested two gene targets (E gene and N gene) with cycle 
threshold (Ct) values used as a proxy for intensity of viral 
load. The RT-PCR test was considered positive if both gene 
targets were detected or if N gene was detected with Ct val-
ue less than 37. The Ct threshold used to determine positivi-
ty was set following three separate calibration experiments. 
First,10 RNA extraction plates were sent from the commer-
cial laboratory for blinded re-analysis in two laboratories 
accredited by the UK Accreditation Service (UKAS). We 
found concordant results for 919 negative samples and all 
40 controls. We detected viral RNA in 11 of the 19 samples 
with a Ct value reported positive by the commercial labora-
tory (N gene Ct value ranging from 16.5 to 40.7); in 10 of 
these 11 samples, N gene Ct value was < 37. Second, in a se-
rial dilution experiment of synthetic SARS-CoV-2 RNA the 
commercial laboratory detected 2.5 copies at Ct 38; also 
while following serial dilution of known positive samples 
with low viral load, the commercial laboratory identified an 
N gene signal at Ct > 37 in most instances. Third, a Public 
Health England (PHE) reference laboratory re-analyzed a 
further 40 unblinded positive samples (on 19 × 96 well 
plates) with N gene Ct values > 35 (range 35.7 to 46.8) and 
without a signal for E gene, detecting SARS CoV-2 RNA in 
15/40 (38%) samples (2/4 with N gene Ct value < 37). The 
results of all three calibration experiments were then con-
solidated to set the positivity criteria noted above, which 
have been used throughout each round of REACT-1. 
 
Prevalence estimates and weighting 
We obtained unweighted (crude) prevalence estimates for 
different sociodemographic and occupational groups by di-
viding counts of swab-positivity (based on RT-PCR) by the 
number of swabs returned in that group. We then applied 
rim weighting (38) to provide prevalence weighted to be 
representative of the population of England as a whole, by: 
age, sex, deciles of the IMD, LTLA counts and ethnic group. 
We obtained the age by sex and LTLA counts from the Of-
fice for National Statistics mid-year population estimates 
(39), counts by ethnic group from the Labor Force Survey 
(40), and calculated the IMD decile points from linkage of 
postcode to area-level IMD using the original sampling 
frame obtained from NHS Digital. Because of the different 
sources of population estimates, the rim weighting was 
based on proportions rather than population totals. We 
grouped age into nine categories: 5 to 12; 13 to 17; 18 to 24; 
25 to 34; 35 to 44; 45 to 54; 55 to 64; 65 to 74; 75 years or 
above, giving 18 age-sex categories. Self-reported ethnicity 
was grouped into nine categories: white; mixed / multiple 
ethnic groups; Indian; Pakistani; Bangladeshi; Chinese; any 
other Asian background; Black African / Caribbean / other; 
and any other ethnic group or missing. 
For the rim weighting, initially (first stage) the sample 
was weighted to LTLA counts and age by sex groups only, 
adjusting the age and sex groups to ensure that the final 
weighted estimates were as close as possible to the popula-
tion profile. Then, using the first stage weights as starting 
weights, the rim weighting was adjusted for all four 
measures, with the adjustment factor between the first and 
second stage weights trimmed at the 1st and 99th percen-
tiles to dampen the extreme weights and improve efficiency. 
The final weights were calculated as the first stage weights 
multiplied by the trimmed adjustment factor for the second 
stage, with confidence intervals for weighted prevalence 
estimates calculated using the “survey” package in R (41). 
 
Statistical analyses 
Statistical analyses were carried out in R (42). To investigate 
the potential confounding effects of covariates on preva-
lence estimates we performed logistic regression on swab 
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type, ethnicity, household size and neighborhood depriva-
tion as explanatory variables. We adjusted for age and sex, 
and mutually adjusted for the other covariates to obtain 
odds ratio estimates and 95% confidence intervals. We de-
cided not to adjust for multiple testing to facilitate direct 
comparisons with other publications where only compari-
son-wise error rate (CER) has been controlled for (43). 
We estimated adjusted VE as 1 – odds ratio where the 
odds ratio was obtained from comparing vaccinated and 
unvaccinated individuals in a logistic regression model with 
swab positivity as outcome and with adjustment for age and 
sex, and age, sex, IMD quintile and ethnicity. 
To estimate the underlying geographical variation in 
prevalence at local (sub-regional) level, we used a neighbor-
hood spatial smoothing method based on nearest neighbor 
up to 30 km. We calculated Nn, the median number of study 
participants within 30 km of each study participant for each 
round or sub-round. We then calculated the local prevalence 
for 15 members of each LTLA as an estimate of the 
smoothed neighborhood prevalence in that area. 
To analyze trends in swab positivity over time, we used 
an exponential model of growth or decay with the assump-
tion that the number of positive samples (from the total 
number of samples) each day arose from a binomial distri-
bution. The model is of the form (t) = I0.e, where I(t) is the 
swab positivity at time t, I0 is the swab positivity on the first 
day of data collection per round and r is the growth rate. 
The binomial likelihood for P (out of N) positive tests on a 
given day is then P ~ (N, I0.ert) based on day of swabbing or, 
if unavailable, day of sample collection. We used a bivariate 
No-U-Turn sampler to estimate posterior credible intervals 
assuming uniform prior distributions on I0 and r (44). We 
estimated the reproduction number R assuming a genera-
tion time that follows a gamma distribution with a shape 
parameter, n, of 2.29 and a rate parameter, β, of 0.36 (corre-
sponding to a mean generation time of 6.29 days) (45). R 
was estimated from the equation R = (1 + r/β)^n (46) using 
data from two sequential rounds and separately per round. 
We carried out a range of sensitivity analyses including es-
timation of R for different thresholds of Ct values that de-
termine swab-positivity and for non-symptomatic 
individuals (not reporting symptoms on the day of swab or 
month prior). 
We fit a Bayesian penalised-spline (P-spline) model (47) 
to the daily data using a No U-Turn Sampler in logit space, 
segmenting the data into approximately 5 day sections by 
regularly spaced knots, with further knots beyond the study 
period to minimise edge effects. We defined 4th order basis-
splines (b-splines) over the knots with the final model con-
sisting of a linear combination of these b-splines. We guard-
ed against overfitting by including a second-order random-
walk prior distribution on the coefficients of the b-splines, 
taking the form bi = 2bi–1 – bi–2 + ui, where bi is the ith b-
spline coefficient and ui is normally distributed with ui ~ 
N(0, ρ2). We assume a constant first derivative for the prior 
distribution which penalises against changes in the growth 
rate unless supported by the data as determined by the pa-
rameter ρ for which we assume an inverse gamma prior 
distribution, ρ ~ IG(0.001, 0.001). We assume the first two b-
spline coefficients have uniform distribution, that is b1 and 
b2 are constant. 
We compared daily prevalence data from rounds 1-13 of 
REACT-1 with publicly available national daily hospital ad-
missions and COVID-19 mortality data (deaths within 28 
days of a positive test). To do this we fit P-spline models as 
before to the daily hospital admissions and to the daily 
death data in order to obtain estimates for the expected 
number of outcomes on a given day. We then fit a simple 
two parameter model consisting of a lag time between the 
posterior of the P-spline estimate for each of hospitalisa-
tions or deaths, and the daily weighted prevalence calculat-
ed from REACT-1 data, and a scaling parameter, 
corresponding to the percentage of people who were swab-
positive in the population on a particular day in comparison 
with future hospitalisations or deaths. Due to the time delay 
between the REACT-1 prevalence signal and daily hospitali-
sations and deaths the model was only fit to rounds 1-12. We 
then compared round 13 data to the estimated trend in hos-
pitalisations and deaths to visualize any alterations in the 
link between these parameters and infection prevalence as 
measured in REACT-1. We estimated these relationships for 
all ages and separately for: those aged under 65 years, and 
those 65 years and above. 
To visualize the trends of the REACT-1 data over time 
we also fitted P-splines to all subsets of the REACT-1 data 
examined. For the REACT-1 data split by age (below 65 
years and 65 years and above) we fit a mixed P-spline model 
in which a P-spline was fit separately to each age group but 
the smoothing parameter, ρ, was fit to both datasets simul-
taneously. Further changes in the first derivative were as-
sumed to happen at the same time for both datasets, with 
the condition ui,<65 – ui,65+ ~ N(0, η2) and η given an unin-
formative prior distribution, η ~ IG(0.001, 0.001). 
 
Viral genome sequencing 
RT-PCR positive swab samples where there was sufficient 
sample volume and with N gene Ct values < 32 were sent 
frozen from the laboratory to the Quadram Institute, Nor-
wich, UK for viral genome sequencing. Amplification of viral 
RNA used the ARTIC protocol (48) and sequencing libraries 
were prepared using CoronaHiT (49). Analysis of sequenc-
ing data used the ARTIC bioinformatic pipeline (50) with 
lineages assigned using PangoLEARN (51). 
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portion of lineages that were identified as the Delta variant 
from round 10 to round 13 to obtain a daily growth rate ad-
vantage between Delta and other circulating lineages, ∆r. 
Assuming an exponential generation time of mean 6.29 days 
(45), the reproduction number, R, is given by 1R r g= + ×  
(46). The estimate of growth rate advantage can thus be 
converted into an additive R advantage through the equa-
tion R r g∆ = ∆ × , assuming the mean generation time is the 
same for all lineages. We chose not to estimate a multiplica-
tive R advantage (52), because it relies on the assumption of 
a zero-variance discrete generation time interval, which is 
less consistent with estimates of an overdispersed serial in-
terval (45). 
As a sensitivity the model was also fit to data from only 
round 11 to round 12 to check that edge effects were not in-
troducing bias. The upper bound of prevalence for non-
Delta lineages (none of which were detected in round 13) 
was estimated by calculating the 95% Wilson upper bound 
on the proportion of non-Delta lineage detected, then mul-
tiplying by the weighted prevalence estimate for round 13. 
This was then multiplied by the population of England to 
get an estimate for the upper bound on the average number 
of people infected with a non-Delta lineage at any one time 
during round 13. 
 
Data availability 
Access to REACT-1 individual-level data is restricted to pro-
tect participants’ anonymity. Summary statistics, descriptive 
tables and code from the current REACT-1 study are availa-
ble at https://github.com/mrc-ide/reactidd. REACT-1 Study 





A Public Advisory Panel provides input into the design, 
conduct and dissemination of the REACT research program. 
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Table 1. Self-reported and linked vaccination status and swab-positivity in rounds 12 and 13 of REACT 1 shown for 
all participants (5 years and over) and for the subset aged 18 to 64 years. 
 




Round 12 Round 13 
Negative Positive Odds ratio Negative Positive Odds ratio 
Self-
reported 
All Unvaccinated 22,709 51 Reference 14,957 178 Reference 
 
Vaccinated (1 dose) 18,654 20 0.48 (0.28, 0.80) 9,598 77 0.67 (0.52, 0.88) 
 
Vaccinated (2 or more doses) 48,383 30 0.28 (0.18, 0.43) 55,765 197 0.30 (0.24, 0.36) 
 
Vaccinated (unknown doses) 2,889 1 0.15 (0.02, 1.12) 3,314 11 0.28 (0.15, 0.51) 
 
Vaccine status not known 16,141 33 0.91 (0.59, 1.41) 14,072 64 0.38 (0.29, 0.51) 
18-64 Unvaccinated  9,012 16 Reference 2,574 28 Reference 
 
Vaccinated (1 dose) 18,307 19 0.58 (0.30, 1.14) 9,467 76 0.74 (0.48, 1.14) 
 
Vaccinated (2 or more doses) 25,248 17 0.38 (0.19, 0.75) 34,503 145 0.39 (0.26, 0.58) 
 
Vaccinated (unknown doses) 1,173 0 0.00 (0.00, NA) 1,517 9 0.55 (0.26, 1.16) 
  Vaccine status not known  10,597 26 1.38 (0.74, 2.58) 9,089 49 0.50 (0.31, 0.79) 
Linked All Unvaccinated 19,115 52 Reference 11,357 153 Reference 
 
Vaccinated (1 dose) 26,285 33 0.46 (0.30, 0.71) 11,885 93 0.58 (0.45, 0.75) 
 
Vaccinated (2 or more doses) 50,721 34 0.25 (0.16, 0.38) 61,202 206 0.25 (0.20, 0.31) 
18-64 Unvaccinated  8,099 21 Reference 1,553 25 Reference 
 
Vaccinated (1 dose) 25,657 32 0.48 (0.28, 0.83) 11,652 92 0.49 (0.31, 0.77) 
  Vaccinated (2 or more doses)  23,511 18 0.30 (0.16, 0.55) 36,448 153 0.26 (0.17, 0.40) 
All Unvaccinated 19,115 52 Reference 11,357 153 Reference 
 
Vaccinated (<14 days 2nd dose) 31,826 35 0.40 (0.26, 0.62) 13,425 102 0.56 (0.44, 0.73) 
 
Vaccinated (≥14 days 2nd dose) 45,180 32 0.26 (0.17, 0.40) 59,662 197 0.25 (0.20, 0.30) 
18-64 Unvaccinated  8,099 21 Reference 1,553 25 Reference 
 
Vaccinated (<14 days 2nd dose) 30,593 34 0.43 (0.25, 0.74) 13,170 101 0.48 (0.31, 0.74) 
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Table 2. Unadjusted and adjusted estimates of vaccine effectiveness against infection for self-
reported vaccine status and linked vaccine status for rounds 12 and 13 of REACT-1 for 
participants aged 18 to 64 years. 
 
Vaccination data source (n) Adjustment Vaccine effectiveness (2 doses) 
Round 12 Round 13 
Self-report, All positives, 18 to 
64 years 
Age, Sex 61% (2%, 84%) 47% (18%, 65%) 
Age, sex, IMD, region, ethnicity 64% (11%, 85%) 49% (22%, 67%) 
Self-report, Symptomatic only, 
18 to 64 years 
Age, Sex 81% (5%, 96%) 56% (19%, 77%) 
Age, sex, IMD, region, ethnicity 83% (19%, 97%) 59% (23%, 78%) 
Linked, All positives, 18 to 64 
years 
Age, Sex 75% (33%, 90%) 61% (36%, 76%) 
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Fig. 1. Temporal trends in prevalence, proportion of positive cases determined to be the Delta variant and vaccine 
coverage. (A) Prevalence of national swab-positivity for England estimated using a P-spline for all thirteen rounds 
with central 50% (dark grey) and 95% (light grey) posterior credible intervals. Shown here from round 5 onwards of 
the study weighted observations (black dots) and 95% binomial confidence intervals (vertical lines) are also shown. 
Note that the period between round 7 and round 8 (December) of the model is not included as there were no data 
available to capture the late December peak of the epidemic. (B) Comparison of the exponential model fit to round 12 
and 13 (blue) and the exponential model fit to round 13 only (red). Also shown is the P-spline model fit from panel A. 
Shown here only for rounds 12 and 13 of the study with a log10 y-axis. (C) Proportion of Delta against Alpha over time. 
Points show raw data with error bars representing the 95% confidence interval. Shaded regions show best fit 
Bayesian logistic regression models, fit to rounds 10 to 13 (green) and rounds 11 to 12 (orange), with 95% credible 
interval. (D) Proportion of individuals, for whom vaccine status is known, who reported being vaccinated with one 

















Fig. 2. Distribution of N-gene Ct values, by vaccine status, for positive samples obtained from individuals 
aged 18-64 years inclusive. (A) Distribution of all N-gene Ct values for those who are unvaccinated (red) and 
those who reported receiving two doses of a vaccine (blue). Also shown are two black dotted lines at N-gene 
Ct equals 35 and N-gene Ct equals 33; these show the threshold values for a sample to be classed as positive 
used in sensitivity analyses. (B) Cumulative density of N-gene Ct values using all available data for 
unvaccinated individuals (red) and individuals who have had two doses of a vaccine (blue). (C) Cumulative 
density of N-gene Ct values using all data in which N-gene Ct is less than 35 for unvaccinated individuals (red) 
and individuals who have had two doses of a vaccine (blue). (D) Cumulative density of N-gene Ct values using 
all data in which N-gene Ct is less than 33 for unvaccinated individuals (red) and individuals who have had two 


















Fig. 3. A comparison of daily deaths and hospitalisations to swab positivity as measured by REACT-1. Daily swab 
positivity for all 13 rounds of the REACT-1 study (black points with 95% confidence intervals, left hand y-axis) with P-spline 
estimates for swab positivity (solid black line, shaded area is 95% confidence interval). (A) Daily deaths in England (red 
points, right hand y-axis) and P-spline model estimates for expected daily deaths in England (solid red line, shaded area is 
95% confidence interval, right hand y-axis). Daily deaths have been shifted by 26 (26, 26) days backward in time along the 
x-axis. The two y-axes have been scaled using the best-fit population adjusted scaling parameter 0.059 (0.058, 0.061). 
(B) Daily hospitalisations in England (blue points, right hand y-axis) and P-spline model estimates for expected daily 
hospitalisations in England (solid blue line, shaded area is 95% confidence interval, right hand y-axis). Daily 
hospitalisations have been shifted by 20 (19, 20) days backward in time along the x-axis. The two y-axes have been scaled 
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